Jan 8, 2008|
US recession, Indian pharma and more...
Crude and gold prices continue to scale higher as investors flock to commodities as investments in wake of the slumping dollar. While crude touched the US$ 100 a barrel mark last week, the figure for gold stood at US$ 861 per ounce. It would seem that a rise in crude prices would curb the demand for oil, which in effect is not happening. Faster growing countries such as India and China continue to guzzle oil helping to keep the demand firm. Besides this, the falling dollar has made the price of oil in other currencies relatively cheaper thereby further preventing oil prices from retreating.
While the falling dollar is just one of the various reasons (some others being geopolitical issues) that is propping up crude prices, it has been the prime catalyst for the rise of gold as the latter is seen as a safe haven in the face of a weakening dollar. Hence, while the US economy looks to be heading towards a recession in 2008 prompted by one of the worst meltdowns in the housing market, rising energy and food prices could fire up inflation thereby leading to the phenomenon called 'stagflation'.
A slew of weak economic reports in the US of late have sparked the downward spiral of the dollar and expectations that the Fed will further cut interest rates when it meets on January 30. For instance, the employment data released last Friday showed that the job growth slowed to the lowest since 2003. The US manufacturing index (highlighting the country's manufacturing activity), slowed to its lowest level since 2003. Not surprisingly, conditions in the housing market continued to deteriorate. In all these reports, the actual results were lower than estimates raising concerns about a possible recession in the US. Interestingly, despite this bleak outlook, the US consumer confidence rose from 87.3 to 88.6.
stocks have failed to entice investors and this can be gauged from the fact that the healthcare index has underperformed the BSE-Sensex for the past three years. The hiccups that the sector had to endure in 2007 were the sharp rupee appreciation, rise in raw material costs as imports of intermediates (used in making bulk drugs) from China got expensive and pricing pressures in the US and some of the European generic markets.
We believe that rising competition, pricing pressure and regulatory risks besides rupee appreciation will continue to plague the sector going forward. Having said that, in the generics space, a rise in the patent expiries of drugs could provide a breather and boost revenues. The focus will shift more towards niche products, which have limited competition and consequently higher margins and biotechnology is quickly emerging as a strong focus area for a majority of leading domestic players. We believe that partnerships are likely to play a crucial role in driving growth. This could be in generics, research, new product introduction and custom manufacturing for innovator companies. For MNC companies, while new product introductions from their parents' folios will be the key to success going forward, the price of the same will most likely be subject to negotiation.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407